Wikipedia

Help:Userspace draft

This is an old revision of this page, as edited by S2kelam (talk | contribs) at 15:04, 30 August 2010 (created new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vestex

Application of Nanotechnology for Medical Textiles.

Vestex™ is an advanced performance textile manufactured by '''Vestagen Technical Textiles LLC''' for healthcare professionals. Vestex™ uses a nanoparticle hydrophobic barrier to repel blood and other bodily fluids commonly found in the healthcare setting. Vestex™ contains a broad spectrum rapidly active EPA registered antimicrobial agent that does not cause or allow the emergence of microbial adaption or resistance. Vestex™ also contains an absorbing hydrophilic technology to help regulate body temperature.

Properties

Vestex™ textiles use a proprietary blend of three patented technologies:

1. NanoSphere®(nano fluorine/silicon oxide)

  • NanoSphere®, a nano-acrylic copolymer dispersion provides natural self-cleaning effects and extremely high water and dirt repellency. NanoSphere® mimics nature’s process using nanoparticles to alter a fiber’s surface. Normally textiles have a smooth surface which provides dirt with a large contact area to which it can easily adhere. NanoSphere® uses fluorine/silicon oxide nanoparticles to create a structured, "hilly" surface that denies a "foothold" for dirt, oil and fluids of any kind. Soil simply runs off or can easily be rinsed off with a little water.

2. SEMELTEC™ (3-(trimethoxysilyl) propyl dimethyl octadecyl ammonium chloride)


3. 3X Dry®

  • 3X Dry® is uniquely composed of both hydrophilic and hydrophobic properties. The hydrophilic properties of this technology allow textiles to wick away moisture from the inside enabling rapid evaporation of moisture, which stimulates a cooling effect, and creates fabrics that dry at a noticeably faster rate. The hydrophobic properties on the outside of the technology protect against bodily fluids and staining as well as resist perspiration from being transported to the outside of the garment. This technology creates textiles that remain breathable, cool, and dry.


Vestex™ technologies are bluesign® standard-approved; ensuring that they are environmentally friendly, pose no health hazards and conserve resources to the greatest possible extent, without compromising functionality, quality or design. Vestex™ technologies have also earned the Hohenstein Institutes Quality Label, independently guaranteeing true nanotechnology, soil repellency, skin compatibility, abrasion resistance, and wash resistance.

Application

 Vestex® textile technology, has advanced active properties; fluid repellency, rapid antimicrobial activity and moisture management. It is advanced because it covers, protects and provides a comfortable, safe environment for both patients and health care workers while reducing the bacterial burden or colony forming units on textiles worn or used in the medical arena.(46,49,50,50)  The data suggests that the hydrophobic fluid repellency properties of the fluorine/silicon oxide-based nanoparticle will prevent gross contamination from biological fluids and other contaminants used in the medical setting. Any remaining or residual organisms that adhere to the textile are then rapidly killed by an ammonia chloride-based antimicrobial impregnated into the textile.  The net impact of the technology will lower the risk of bacteria being acquired, retained and transmitted via textiles while maintaining the comfort properties required by medical personnel and patients who wear and use the products.

Importance

The rates of nosocomial infections, especially by those caused by antibiotic resistant bacteria, are increasing alarmingly across the globe.(1-10) Nosocomial infections are now also spreading out from the hospital environment into the community.(11,12) It is estimated that by using several strategies about one third of these infections can be prevented.(10,13) It is widely agreed that hand washing is the most important method to decrease nosocomial infection in the hospital setting (14, 15), but, sadly, this hygiene action is often lacking.(10,16,17) Although more rigorous infection control measures are being implemented, it is clear that the current modalities to reduce nosocomial infections are not sufficient.(10,18,19)

Numerous studies indicate that bacteria can thrive on medical fabrics.(20) Textiles used in the healthcare environment are an excellent substrate for bacterial growth due to the moisture and temperature conditions.(21) Patients shed bacteria and contaminate their pajamas and sheets and healthcare workers have been shown to acquire, carry and spread pathogens.(22-29) Medical personnel in direct or indirect contact with contaminated surfaces, including textiles, are a source of transmission of the micro-organisms to susceptible patients.(25,26,30) Furthermore, it has been reported that bed making in hospitals releases large quantities of micro-organisms into the air, which contaminate the immediate and non-immediate surroundings.(31) Contaminated textiles in hospitals and other medical facilities can thus be an important source of infectious microbes contributing to endogenous, indirect-contact, and aerosol transmission of nosocomial related pathogens.(32,33) Healthcare fabric, whether it’s uniforms/scrubs, patient gowns and bed linens, furniture or privacy curtains, are proven to carry and retain pathogenic organisms in the healthcare environment and is becoming a bigger issue in the fight against healthcare-acquired infections.(32,34)

The use of technologically advanced performance textiles, such as Vestex® textile technology, especially in products that are in close contact with patients, healthcare workers and visitors, can reduce bio-burden in clinical settings and consequently reduce the risk of nosocomial infections.

References

  1. Nguyen QV. Hospital-acquired infections. 2006, http://www.emedicine.com/ped/topic1619.htm.
  2. Klevens RM, Edwards JR, Richards Jr CL, et al. Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep 2007;122:160–6.
  3. Eric Jozsef. L’Italie scandalis’e par «l’hopital de l’horreur ». Liberation. January 15, 2007.
  4. Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello P. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005;60:93–103.
  5. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med 2006;3:e494.
  6. Hughes AJ, Ariffin N, Huat TL, et al. Prevalence of nosocomial infection and antibiotic use at a university medical center in Malaysia. Infect Control Hosp Epidemiol 2005;26:100–4.
  7. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003;111:1265–73.
  8. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50–5.
  9. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillinresistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582–6.
  10. Weinstein RA. Nosocomial infection update. Emerg Infect Dis 1998;4:416–20.
  11. Olesevich M, Kennedy A. Emergence of community acquired methicillin-resistant Staphylococcus aureus soft tissue infections. J Pediatr Surg 2007;42:765–8.
  12. Beumer et al, THE INFECTION POTENTIAL IN THE DOMESTIC SETTING AND THE ROLE OF HYGIENE PRACTICE IN REDUCING INFECTION, International Scientific Forum on Home Hygiene. August 2002
  13. Scheckler WE, Brimhall D, Buck AS, et al. Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: a consensus panel report.
  14. McGuckin M, Waterman R, Porten L, et al. Patient education model for increasing hand washing compliance. Am J Infect Control 1999;27:309–14.
  15. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000;356:1307–12.
  16. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin Microbiol Rev 2004;17:863–93.
  17. Ayliffe GA, Babb JR, Davies JG, Lilly HA. Hand disinfection: a comparison of various agents in laboratory and ward studies. J Hosp Infect 1988;11:226–43.
  18. Pratt RJ, Pellowe CM, Wilson JA, et al. Epic2: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2007;65(Suppl 1):S1–S64.
  19. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1998;19:114–24.
  20. Pyrek K, Medical Fabrics: A Reservoir of Pathogenic Bacterium? http://www.infectioncontroltoday.com/ 12/31/2008
  21. Borkow G, Gabbay J. Biocidal textiles can help fight nosocomial infections. Medical Hypotheses 2008; 70,990-994
  22. Beggs CB. The airborne transmission of infection in hospital buildings: fact or fiction? Indoor Built Environ 2003;12:9–18.
  23. Coronel D, Escarment J, Boiron A, et al. Infection et contamination bacterienne de l’environnement des patients: les draps. Reanimation 2001;10S:43–4.
  24. CDC. Fact Sheet. 2007, http://www.cdc.gov/ncidod/hip/Aresist/mrsafaq.htm.
  25. Boyce JM, Potter-Bynoe G, Chenevert C, King T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol 1997;18:622–7.
  26. Boyce JM, Potter-Bynoe G, Chenevert C, King T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol 1997;18:622–7.
  27. Takahashi A, Yomoda S, Tanimoto K, Kanda T, Kobayashi I, Ike Y. Streptococcus pyogenes hospital-acquired infection within a dermatological ward. J Hosp Infect 1998;40:135–40.
  28. Gustafson TL, Kobylik B, Hutcheson RH, Schaffner W. Protective effect of anticholinergic drugs and psyllium in a nosocomial outbreak of Norwalk gastroenteritis. J Hosp Infect 1983;4:367–74.
  29. http://www.outbreak-database.com, 2007.
  30. Gastmeier P, Stamm-Balderjahn S, Hansen S, et al. Where should one search when confronted with outbreaks of nosocomial infection? Am J Infect Control 2006;34:603–5.
  31. Solberg CO. A study of carriers of Staphylococcus aureus with special regard to quantitative bacterial estimations. Acta Med Scand Suppl 1965;436:1–96.
  32. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006;6:130.
  33. Borkow G, Gabbay J. Biocidal textiles can help fight nosocomial infections. Medical Hypotheses 2008; 70,990-994
  34. Pyrek K, Medical Fabrics: A Reservoir of Pathogenic Bacterium? http://www.infectioncontroltoday.com/ 12/31/2008
  1. http://www.bluesign.com/index.php?id=52
  2. http://www.hohenstein.de/en/index.asp
  3. http://vestexprotects.com/
  4. http://vestagen.com/
Retrieved from "https://en.wikipedia.org/w/index.php?title=Help:Userspace_draft&oldid=381890215"